Study Agent

PreclinicalSmall molecule

OOregon Health and Science University

Study Agent is one of 7 small molecule programs targeting Smokers. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SmokersRecruiting

SmokersPreclinical

Recruiting

Competition

Competitive Landscape

7 competitors in Smokers

#DrugCompanyPhaseTrials

Chantix

Pfizer

Phase 3

3 2

Epivir

GGlaxo Dba Glaxosmithkline

Phase 1

1 3

Rapamycin

MMaastricht Radiation Oncology

Phase 1

1 4

Nicotine Lozenge

FFertin Pharma A/S

Preclinical

1 5

Reduced Nicotine Content Cigarettes

MMilton S. Hershey Medical Center

Preclinical

1 6

Pharmacological

UUniversity of Virginia

Preclinical

1 7

Study Agent

OOregon Health and Science University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Smokers1 trial

Effects of a Specific Substance in Smokers

Recruiting·OOregon Health and Science University·N/A·NCT04281979·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Study Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Study Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Study Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oregon Health and Science University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOregon Health and Science University

Study Agent

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Smokers1 trial

References

Drug Info

Quick Facts

Related News